222 related articles for article (PubMed ID: 28689831)
21. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
Qi Y; Musson DG; Schweighardt B; Tompkins T; Jesaitis L; Shaywitz AJ; Yang K; O'Neill CA
Clin Pharmacokinet; 2014 Dec; 53(12):1137-47. PubMed ID: 25234648
[TBL] [Abstract][Full Text] [Related]
22. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.
Burton BK; Berger KI; Lewis GD; Tarnopolsky M; Treadwell M; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Genter F; Shaywitz AJ; Harmatz P
Am J Med Genet A; 2015 Oct; 167A(10):2272-81. PubMed ID: 26069231
[TBL] [Abstract][Full Text] [Related]
23. Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
Melton AC; Soon RK; Tompkins T; Long B; Schweighardt B; Qi Y; Vitelli C; Bagri A; Decker C; O'Neill CA; Zoog SJ; Jesaitis L
J Immunol Methods; 2017 Jan; 440():41-51. PubMed ID: 27789297
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
Sánchez-Morillas L; Casado Herráez A; Rubio-Perez M; Robledo Echarren T; González Gutiérrez ML; Cimarra M; Vázquez Cortés S; Cerecedo I; Fernández-Rivas M
J Investig Allergol Clin Immunol; 2020; 30(4):298-300. PubMed ID: 32101175
[No Abstract] [Full Text] [Related]
25. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
Lee CL; Chuang CK; Chiu HC; Tu RY; Lo YT; Chang YH; Lin SP; Lin HY
Drug Des Devel Ther; 2022; 16():143-154. PubMed ID: 35046639
[TBL] [Abstract][Full Text] [Related]
28. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.
Hendriksz CJ; Berger KI; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Matousek R; Jurecki E; Decker C; Harmatz PR
J Inherit Metab Dis; 2016 Nov; 39(6):839-847. PubMed ID: 27553181
[TBL] [Abstract][Full Text] [Related]
29. Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
Harmatz P
Clin Ther; 2015 Sep; 37(9):2130-4. PubMed ID: 26243075
[TBL] [Abstract][Full Text] [Related]
30. Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.
Barailler H; Milpied B; Chauvel A; Claraz P; Taïeb A; Seneschal J; Darrigade AS
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):307-308. PubMed ID: 29800755
[No Abstract] [Full Text] [Related]
31. Successful Elosulfase Alfa Desensitization Protocol in a Patient With Morquio A Syndrome.
Díaz Vidal VC; Gillispie A; Aranda C; Anvari S
Pediatrics; 2022 Feb; 149(2):. PubMed ID: 35059725
[TBL] [Abstract][Full Text] [Related]
32. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment.
DuBuske I; Schmidlin K; Bernstein JA
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):96-98. PubMed ID: 32866621
[No Abstract] [Full Text] [Related]
33. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
[TBL] [Abstract][Full Text] [Related]
34. Successful desensitization in a pediatric patient with acetazolamide allergy.
Carlisle A; Kennedy JL; Chervinskiy S; Jones SM; Pesek RD
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):508-509. PubMed ID: 29966705
[No Abstract] [Full Text] [Related]
35. Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization.
González-de-Olano D; Morgado JM; Juárez-Guerrero R; Sánchez-Muñoz L; Letellez-Fernández J; Malón-Giménez D; Castells MC
J Allergy Clin Immunol Pract; 2016; 4(2):338-40. PubMed ID: 26725157
[No Abstract] [Full Text] [Related]
36. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart FJ; Hughes DA; Matousek R; Hawley SM; Decker C; Harmatz PR
Mol Genet Metab; 2018 Feb; 123(2):127-134. PubMed ID: 29248359
[TBL] [Abstract][Full Text] [Related]
37. Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.
Sosa AC; Kariuki B; Gan Q; Knutsen AP; Bellone CJ; Guzmán MA; Barrera LA; Tomatsu S; Chauhan AK; Armbrecht E; Montaño AM
J Clin Invest; 2020 Mar; 130(3):1288-1300. PubMed ID: 31743109
[TBL] [Abstract][Full Text] [Related]
38. Trial watch: enzyme replacement success in Phase III trial for rare metabolic disorder.
Crunkhorn S
Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274460
[No Abstract] [Full Text] [Related]
39. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.
Schrover R; Evans K; Giugliani R; Noble I; Bhattacharya K
Orphanet J Rare Dis; 2017 Apr; 12(1):78. PubMed ID: 28441951
[TBL] [Abstract][Full Text] [Related]
40. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement.
Stevens B; Kenny T; Thomas S; Morrison A; Jarrett J; Jain M
Orphanet J Rare Dis; 2021 Sep; 16(1):394. PubMed ID: 34563214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
